首站-论文投稿智能助手
典型文献
Discovery of novel KRAS-PDEδ inhibitors with potent activity in patient-derived human pancreatic tumor xenograft models
文献摘要:
KRAS-PDEδ interaction is revealed as a promising target for suppressing the function of mutant KRAS.The bottleneck in clinical development of PDEδ inhibitors is the poor antitumor activity of known chemotypes.Here,we identified novel spiro-cyclic PDEδ inhibitors with potent antitumor ac-tivity both in vitro and in vivo.In particular,compound 361(KD=127±16 nmol/L)effectively bound to PDEδ and interfered with KRAS-PDEδ interaction.It influenced the distribution of KRAS in Mia PaCa-2 cells,downregulated the phosphorylation of t-ERK and t-AKT and promoted apoptosis of the cells.The novel inhibitor 361 exhibited significant in vivo antitumor potency in pancreatic cancer patient-derived xenograft(PDX)models.It represents a promising lead compound for investigating the druggability of KRAS-PDEδ interaction.
文献关键词:
作者姓名:
Long Chen;Jing Zhang;Xinjing Wang;Yu Li;Lu Zhou;Xiongxiong Lu;Guoqiang Dong;Chunquan Sheng
作者机构:
School of Pharmacy,Second Military Medical University,Shanghai 200433,China;Department of Pathology,Changzheng Hospital,Second Military Medical University,Shanghai 200003,China;Department of General Surgery,Pancreatic Disease Center Ruijin Hospital,Shanghai Jiao Tong University,Shanghai 200025,China;Research Institute of Pancreatic Diseases,Shanghai Jiao Tong University School of Medicine,Shanghai 200025,China;Department of Medicinal Chemistry,School of Pharmacy,Fudan University,Shanghai 201203,China
引用格式:
[1]Long Chen;Jing Zhang;Xinjing Wang;Yu Li;Lu Zhou;Xiongxiong Lu;Guoqiang Dong;Chunquan Sheng-.Discovery of novel KRAS-PDEδ inhibitors with potent activity in patient-derived human pancreatic tumor xenograft models)[J].药学学报(英文版),2022(01):274-290
A类:
Mia,druggability
B类:
Discovery,novel,KRAS,PDE,inhibitors,potent,activity,patient,derived,human,pancreatic,xenograft,models,interaction,revealed,as,promising,target,suppressing,function,mutant,bottleneck,clinical,development,poor,antitumor,known,chemotypes,Here,we,identified,spiro,cyclic,both,vitro,vivo,In,particular,compound,KD,nmol,effectively,bound,interfered,It,influenced,distribution,PaCa,cells,downregulated,phosphorylation,ERK,AKT,promoted,apoptosis,exhibited,significant,potency,cancer,PDX,represents,lead,investigating
AB值:
0.531755
相似文献
Defined tumor antigen-specific T cells potentiate personalized TCR-T cell therapy and prediction of immunotherapy response
Jingjing He;Xinxin Xiong;Han Yang;Dandan Li;Xuefei Liu;Shuo Li;Shuangye Liao;Siyu Chen;Xizhi Wen;Kuai Yu;Lingyi Fu;Xingjun Dong;Kaiyu Zhu;Xiaojun Xia;Tiebang Kang;Chaochao Bian;Xiang Li;Haiping Liu;Peirong Ding;Xiaoshi Zhang;Zhenjiang Liu;Wende Li;Zhixiang Zuo;Penghui Zhou-State Key Laboratory of Oncology in Southern China,Collaborative Innovation Center for Cancer Medicine,Sun Yat-sen University Cancer Center,Guangzhou,China;Guangdong Provincial People's Hospital,Guangdong Academy of Medical Sciences,Guangzhou,China;Guangdong Laboratory Animals Monitoring Institute,Guangdong Key Laboratory of Laboratory Animals,Guangzhou,China;Guangzhou Finelmmune Biotechnology Co.,LTD,Guangzhou,China
P300/CBP inhibition sensitizes mantle cell lymphoma to PI3Kδ inhibitor idelalisib
Xiao-ru Zhou;Xiao Li;Li-ping Liao;Jie Han;Jing Huang;Jia-cheng Li;Hong-ru Tao;Shi-jie Fan;Zhi-feng Chen;Qi Li;Shi-jie Chen;Hong Ding;Ya-xi Yang;Bing Zhou;Hua-liang Jiang;Kai-xian Chen;Yuan-yuan Zhang;Chuan-xin Huang;Cheng Luo-Drug Discovery and Design Center,The Center for Chemical Biology,State Key Laboratory of Drug Research,Shanghai Institute of Materia Medica,Chinese Academy of Sciences,Shanghai 201203,China;University of Chinese Academy of Sciences,Beijing 100049,China;School of Life Science and Technology,ShanghaiTech University,Shanghai 200031,China;Department of Medicinal Chemistry,State Key Laboratory of Drug Research,Shanghai Institute of Materia Medica,Chinese Academy of Sciences,Shanghai 201203,China;Shanghai Institute of Immunology and Department of Immunology and Microbiology,Key Laboratory of Cell Differentiation and Apoptosis of Chinese Ministry of Education,Faculty of Basic Medicine,Shanghai Jiao Tong University School of Medicine,Shanghai 200025,China
Upregulation of wild-type p53 by small molecule-induced elevation of NQO1 in non-small cell lung cancer cells
Hong Yu;Hong-ying Gao;Hua Guo;Gui-zhen Wang;Yi-qing Yang;Qian Hu;Li-jun Liang;Qun Zhao;Da-wei Xie;Yu Rao;Guang-biao Zhou-School of Chinese Materia Medica,Beijing University of Chinese Medicine,Beijing 100029,China;State Key Laboratory of Molecular Oncology,National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100021,China;MOE Key Laboratory of Protein Sciences,School of Pharmaceutical Sciences,MOE Key Laboratory of Bioorganic Phosphorus Chemistry&Chemical Biology,and School of Medicine and Collaborative Innovation Center of Biotherapy,Tsinghua University,Beijing 100084,China;Hubei University of Medicine,Shiyan 442000,China
The novel indomethacin derivative CZ-212-3 exerts antitumor effects on castration-resistant prostate cancer by degrading androgen receptor and its variants
Hong Wang;Zhe Chang;Guo-di Cai;Ping Yang;Jiang-he Chen;Shan-shu Yang;Yin-feng Guo;Ming-yu Wang;Xue-hua Zheng;Jin-ping Lei;Pei-qing Liu;De-peng Zhao;Jun-jian Wang-School of Pharmaceutical Sciences,Sun Yat-sen University,Guangzhou 510006,China;State Key Laboratory of Oncology in South China,Collaborative Innovation Center for Cancer Medicine,Guangzhou 510060,China;Department of Pathology,Sun Yat-sen University Cancer Center,Guangzhou 510060,China;Key Laboratory of Molecular Target and Clinical Pharmacology,School of Pharmaceutical Sciences and the Fifth Affiliated Hospital,Guangzhou Medical University,Guangzhou 510006,China;Guangdong Provincial Key Laboratory of New Drug Design and Evaluation,School of Pharmaceutical Sciences,Sun Yat-sen University,Guangzhou 510006,China;National-Local Joint Engineering Laboratory of Druggability and New Drugs Evaluation,Sun Yat-sen University,Guangzhou 510006,China
Okicamelliaside targets the N-terminal chaperone pocket of HSP90 disrupts the chaperone protein interaction of HSP90-CDC37 and exerts antitumor activity
Chuan-jing Cheng;Kai-xin Liu;Man Zhang;Fu-kui Shen;Li-li Ye;Wen-bo Wu;Xiao-tao Hou;Er-wei Hao;Yuan-yuan Hou;Gang Bai-State Key Laboratory of Medicinal Chemical Biology,College of Pharmacy and Tianjin Key Laboratory of Molecular Drug Research,Nankai University,Tianjin 300353,China;Collaborative Innovation Center of Research on Functional Ingredients from Agricultural Residues,Guangxi Key Laboratory of Efficacy Study on Chinese Materia Medica,Guangxi University of Chinese medicine,Nanning 530200,China;China-ASEAN Joint Laboratory for International Cooperation in Traditional Medicine Research,Guangxi University of Chinese Medicine,Nanning 530200,China
Pharmacodynamic,pharmacokinetic,and phase 1a study of bisthianostat,a novel histone deacetylase inhibitor,for the treatment of relapsed or refractory multiple myeloma
Yu-bo Zhou;Yang-ming Zhang;Hong-hui Huang;Li-jing Shen;Xiao-feng Han;Xiao-bei Hu;Song-da Yu;An-hui Gao;Li Sheng;Ming-bo Su;Xiao-li Wei;Yue Zhang;Yi-fan Zhang;Zhi-wei Gao;Xiao-yan Chen;Fa-jun Nan;Jia Li;Jian Hou-National Center for New Drug Screening,State Key Laboratory of Drug Research,Shanghai Institute of Materia Medica,Chinese Academy of Sciences,Shanghai 201203,China;University of Chinese Academy of Sciences,Beijing 100049,China;Yantai Key Laboratory of Nanomedicine&Advanced Preparations,Yantai Institute of Materia Medica,Yantai 264000,China;Department of Hematology,Renji Hospital,Shanghai Jiaotong University School of Medicine,Shanghai 200127,China;Shanghai Center for Drug Metabolism and Pharmacokinetics Research,Shanghai 201203,China
机标中图分类号,由域田数据科技根据网络公开资料自动分析生成,仅供学习研究参考。